Evaluation of the Anti-Tumor Activity of Small Molecules Targeting Eph/Ephrins in APC
APC min/J mice
Eph antagonist
Eph-ephrin system
EphA receptors
EphB receptors
Familial adenomatous polyposis (FAP)
UniPR129
colorectal cancer (CRC)
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
16 Apr 2020
16 Apr 2020
Historique:
received:
31
03
2020
revised:
12
04
2020
accepted:
14
04
2020
entrez:
23
4
2020
pubmed:
23
4
2020
medline:
23
4
2020
Statut:
epublish
Résumé
The Eph receptors are the largest receptors tyrosine kinases (RTKs) family in humans and together with ephrin ligands constitute a complex cellular communication system often dysregulated in many tumors. The role of the Eph-ephrin system in colorectal cancer (CRC) has been investigated and different expression of Eph receptors have been associated with tumor development and progression. In light of this evidence, we investigated if a pharmacological approach aimed at inhibiting Eph/ephrin interaction through small molecules could prevent tumor growth in APC
Identifiants
pubmed: 32316101
pii: ph13040069
doi: 10.3390/ph13040069
pmc: PMC7243115
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : 15211
Références
Nature. 2015 May 14;521(7551):S1
pubmed: 25970450
Int J Cancer. 2009 Mar 15;124(6):1366-71
pubmed: 19089910
Nat Genet. 2007 Nov;39(11):1376-83
pubmed: 17906625
Nat Rev Mol Cell Biol. 2016 Apr;17(4):240-56
pubmed: 26790531
Cancer Res. 2009 Sep 15;69(18):7430-8
pubmed: 19738063
Br J Pharmacol. 2014 Dec;171(23):5195-208
pubmed: 24597515
J Pharm Biomed Anal. 2020 Feb 20;180:113067
pubmed: 31891876
Biochim Biophys Acta. 1997 Apr 18;1332(2):F25-48
pubmed: 9141462
Pharmacol Res. 2019 Mar;141:319-330
pubmed: 30625359
J Med Chem. 2017 Jan 26;60(2):787-796
pubmed: 28005388
Cancer Res. 2009 May 1;69(9):3736-45
pubmed: 19366806
Eur J Cancer. 1995 Jul-Aug;31A(7-8):1061-4
pubmed: 7576992
Br J Cancer. 2009 Apr 7;100(7):1095-102
pubmed: 19277044
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Clin Cancer Res. 2016 Jan 1;22(1):230-242
pubmed: 26283684
Carcinogenesis. 2009 Sep;30(9):1475-86
pubmed: 19483190
Nature. 2005 Jun 23;435(7045):1126-30
pubmed: 15973414
Eur J Med Chem. 2015 Oct 20;103:312-24
pubmed: 26363867
J Oncol. 2010;2010:135285
pubmed: 20224755
Eur J Cancer. 2012 Mar;48(5):753-62
pubmed: 21852108
Oncotarget. 2018 May 11;9(36):24347-24363
pubmed: 29849945
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Carcinogenesis. 2006 Mar;27(3):454-64
pubmed: 16272170
Cancer Sci. 2004 Feb;95(2):136-41
pubmed: 14965363
Curr Opin Cell Biol. 1997 Oct;9(5):608-15
pubmed: 9330863
Cancer Res. 2007 Oct 15;67(20):9721-30
pubmed: 17942902
Biochem Pharmacol. 2018 Jan;147:21-29
pubmed: 29129483